

CURRICULUM VITAE

NATHAN VISWESHWAR, M.D
University of South Florida,
Morsani College of Medicine
13330 USF Laurel Dr. 4th Floor
Tampa, FL 33612
813 974 3725
nviswesh@health.usf.edu

- Present appointment:** Assistant Professor of Medicine
Division of Hematology
Department of Internal Medicine
University of South Florida
Tampa, Florida
- Board certification:** American Board of internal medicine 2003, 2013
American Board of Medical Oncology 2006, 2016
FRCPC (Hem.) – since 1994
- Medical licensure:** Florida, ME97021
- Military status:** None
- Education:** Medical degree - Madras Medical College
University of Madras – M.B., B.S – 1975
- Training:** -Internship: July 2000- Dec. 2002
Mount Sinai School Program at Jersey City Medical Center, NJ
-Fellowship: Jan.2003 – June 2005
Fellowship in Hematology, Oncology and Bone Marrow Transplantation
at Seton Hall University Program at St. Joseph’s Regional Medical
Center. NJ
- Academic appointments:** -Assistant Professor Medicine, University of South Florida College of
Medicine, Department of Internal Medicine July 2013 – till date
-Assistant Professor Medicine, University of West Virginia, Department
of hematology/oncology - July 2005-January 2007
-Assistant Professor Medicine, Dept. of Hematology, University of
Madras, Department of hematology - July 1997-June 2000

Administrative Appointments:

- Attending physician, Hemophilia program, University of South Florida -
- Attending physician - Infusion services, University of South Florida -July
- Attending physician, hematology section-James V Haley Veterans Administration Hospital, Tampa, Florida
- Attending physician, hematology section-Tampa General Hospital, Tampa, Florida

Organizations:

- Fellow, American College of Physicians (FACP)– since 2011
- Fellow, Royal College of Physicians (FRCP) - since 1997
- Fellow, Royal College of Pathologists (FRCPath.) - Since 1994
- Fellow, Royal Society of Medicine - since 1994

Awards:

Obtained the gold medal for the best outgoing student in MD program

Professional experience:

- Postgraduate training in medicine at Stanley Hospital in University of Madras – Madras, India Apr. '75 - Mar. '78
- Honorary Assistant physician at Stanley Hospital in University of Madras - Apr.'78-Mar.'79
- Senior house officer in geriatric medicine at Christchurch Hospital, Christchurch, Dorset UK. May '79 – April '80
- Senior house officer in emergency medicine, Mansfield district General Hospital, Mansfield, UK. July '80-June '82
- Registrar in medicine and chest diseases at Bucknall Hospital, Stoke on Trent, UK Sep. '82-Aug. '83
- Senior Registrar in hematology at St. James's University Hospital, Leeds, UK Sept '85-Aug '88
- Consultant hematologist at King Fahad specialist hospital, Buraidah, Saudi Arabia Sep. '88-Dec. '94
- Consultant in Bone marrow transplantation at Apollo Hospital, Madras-Jan.'95- Jun.'97

Scholarly activity:*Papers published in 2016/2017*

1. Paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia- **Visweshwar N**, Jaglal M, Booth C, Griffin P, Laber D. Ann Hematol. 2016 Oct;95(10):1747-9. doi: 10.1007/s00277-016-2752-5. Epub 2016 Jul 23. PMID: 27449072
2. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Sam C, Desai P, Laber D, Patel A, **Visweshwar N**, Jaglal M. Transfus Med. 2017 Apr 12. doi: 10.1111/tme.12407. [Epub ahead of print]PMID: 28401611|IgG4-

3. Nivolumab as salvage treatment in a patient with HIV-related Relapsed and refractory Hodgkin lymphoma and liver failure with encephalopathy. Sandoval-Sus JD, Mogollon-Duffo F, Patel A, **Visweshwar N**, Laber DA, Kim R, Jagal MV. J Immunother Cancer. 2017 Jun 20;5:49. PubMed PMID: 28642818.
4. A meta-analysis of low molecular weight heparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer -Jaglal Michael, **Nathan Visweshwar**, and Benjamin Djulbegovic. American Journal of hematology. Vol. 91. E363-E365 , 2016.
5. Validation of the Khorana Score in a Large Cohort of Cancer Patients with Venous Thromboembolism - Chaudhury A, Balakrishnan A, Thai C, Holmstrom B, Nanjappa S, Ma Z, Zhou J, Patel A, **Visweshwar N**, Jaglal MV. (2016): 876-879 Thrombosis & Hemostasis
6. Accidental and Surreptitious Intake of Oral Anticoagulants Including Older and Newer Agents - A Diagnostic Dilemma **Visweshwar N**, Patel A, Jaglal M & Laber D - J Hematol Thromb 3(1): 3 (2017) 201-03
7. Is Warfarin Obsolete? - **Visweshwar N**, Malachowski S, Jaglal M and Laber D. J Oncol Hematol. 2016; 1(1): 1002 -1004.
8. IgG4 Related Disorder Masquerading as an Indurated Skin Lesion - **Nathan Visweshwar**, Michael Jaglal, Stephen Malachowski, Sana Azam, Damian Laber, Patrick Griffin - J Hematol. 2016;5(3):113-115
9. Bloodless Surgery in Jehovah's Witness-a critical review - **Visweshwar N**, Jaglal N. J Hem Diseases Therapies 2017: 106 -10.
10. Recurrent Venous Thromboembolism- Its Causes, Prevention and Management. Hematol Transfus Int.J **Visweshwar N**, Jaglal M, Sokol 5(1): 00109. DOI: 10.15406/htij.2017
11. Chemotherapy-related anemia - **Visweshwar N**, Jaglal M, Sokol L, Zuckerman K.. Ann. of Hematol 10.1007/s00277-017-3155 - 2017

Systematic reviews in preparation:

1. "Value of Ultrasonography in the treatment of Hemophilia – a systematic review"
Visweshwar N, Malachowsky S and Kumar A
2. "Thrombopoietin mimetics in management of therapeutic interventions in cirrhosis of the liver"-Meta-analysis- Visweshwar N, Mhaskar R and Djulbegovic B- USF Health Program for Comparative Effectiveness Research and Evidence Based Medicine.

Book Chapter:

Chapter on etiological factors in Leukemia: CAUSES, SYMPTOMS & TREATMENT published by Claudia Scotti, open access (Wilmington, DE 19801, USA)

Invited lectures:

1) International:

- a) Invited to speak in the 5th World Hematologists congress conference in London– Aug. 2016 - Title: "Treatment in Hemophilia patients based on patient's perception of a joint bleed - impact on resources in developing countries" – London, UK - Katsia Morris, *Program Coordinator*, Ph: 702-508-5200 (8062)
- b) "Intracranial Hemorrhage and Newer oral anticoagulants" – Guest lecture on Oct 4th 2016 at the International Conference in Hematology, Orlando – Program Coordinator Alisha Summer Ph: 407 943 0585
- c) Guest Speaker - Indian Society of hematology and blood transfusion-annual conference - 2013, 2014

2) National:

- a) Guest speaker "Hemophilia & HIV" in 68th National Hemophilia Federation Annual Meeting, held on July 21- 23, 2016 in Orlando, Florida. July 2016

3) Regional:

- a) Grand Rounds lecture on Thursday, October 23rd 2015 on "Coagulation cascade" at Orlando Regional Medical Center, a division of Orlando Health

4) Local:

- a) Grand round in USF- "Oral anticoagulant therapy" - 05/2015

Papers under preparation:

1. Thrombopoietin mimetics in the management of invasive procedures in cirrhosis of the liver – a systematic review – Visweshwar N, Kumar A and Mhaskar R
2. Value of ultrasonography in hemophilia-systematic review- –Visweshwar , milidinovic and Djulbegovic

Current CDC/ATHN hemophilia protocols:

1. Protocol 6123-1103: "Public health Surveillance for the Prevention of Complications of Bleeding and Clotting" (flow through: CDC) / ATHN - Principal Investigator
2. Protocol 6123-1145: "H30MC24046 Southeast Region Comprehensive Bleeding Disorders Treatment Program" (federal flow through: HRSA) - Principal Investigator
3. Protocol 000015970 (not human research activities determination) and all three parts of Community Counts: HTC Population Profile, Mortality Reporting. CDC Public Health Surveillance Project for Bleeding Disorders - Principal Investigator
4. Project Number: ATHN2015-MLOF-2 - My Life, Our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository - Principal Investigator

5. Protocol 061302 Study of Prophylaxis, Activity and Effectiveness (SPACE) in Hemophilia Patients Currently treated with ADVATE or RIXUBIS - Principal Investigator

Gene studies:

SB-525 -1603 study [AAV2/6 human Factor VIII Gene Therapy] in adult Subjects with Severe Hemophilia A

Blood substitute studies:

Study - NCT02411708 - SANGUINATE (Pegylated bovine carboxyhaemoglobin) In the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis

Papers presented:

1. Meta-analysis of Low Molecular Weight Heparin versus Vitamin K Antagonist for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. Michael Jaglal, MD. MS. Nathan Visweshwar, MD Benjamin Djulbegovic, MD, PHD - University of South Florida/Moffitt Cancer Center – oral presentation ATHN meet 2014
2. 2015 Moffitt Scientific Symposium Abstract - Prevalence of genetic mutations in patients with venous thromboembolism: retrospective study from a teaching center’s experience - Emole J, Azam S, Badru M, Visweshwar N and Jaglal M
3. Correlation of CD3 and CD34 cell dose with incidence of acute GVHD in myeloablative stem cell transplantation - Saad, A., N. Visweshwar, A. Sehbai, A. Cumpston, K. Watkins, R. Buckhalter, G. Hobbs, J. Abraham, and S. Ericson. *Journal of Clinical Oncology* 24, no. 18_suppl (2006): 6553-6553.
4. Role of quantitative viral load monitoring of BK virus in hemorrhagic cystitis complicating HSCT patients - Grantham, K. Nath, R., Visweshwar, N., et al. *Biology of Blood and Marrow Transplantation* 12.2 (2006): 110.
5. Thrombolysis of acute portal vein thrombus - Al Haq SM, Visweshwar NI, Contractor QQ. *Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology*. 1996 Jan;15(1):22-3
6. Autologous and allogeneic peripheral blood stem cell transplants without manipulation nor cryopreservation in a developing country (India) - Lakshman, V., Visweshwar, N. et al. *Int J Haematol* 64.Suppl 1 (1996): s154.
7. White clot syndrome - heparin-induced platelet aggregation: A case report. Adebonojo SA, Nova G, Visweshwar IN. *Ann Saudi Med*. 1991 Nov;11(6):698-700.
8. A Case Of Fever With Maculopapular Rash—Evidence Based Approach - Sudheendra, R., N. Patel, and I. Visweshwar. *Journal of General Internal Medicine* 17 (2002): 72.

9. Relationship of BK viral load in blood and urine with the severity of hemorrhagic cystitis (HC) after hematopoietic stem cell transplantation (HSCT) - Janbay, N., De Bari, V., Manna, P., Visweshwar, N., David, C., Lange, M., ... & Nath, R. (2005).. *Biology of Blood and Marrow Transplantation*, 11(2), 74.
10. Matched and mismatched unrelated cord blood (UCB) stem cell transplant (SCT) in adults: preliminary results of an ongoing prospective trial. Chen, W., Stives, S., Visweshwar, N., Diaz, B., Yanbey, N., Ojha, R., ... & Nath, R. (2004). *Biology of Blood and Marrow Transplantation*, 10, 37.
11. Reversible Severe Bradycardia And Asystole Induced By Transient Hypoxia - Alwani, A., Sudheendra, R., Visweshwar, I., & Ameen, A. (2002). *Journal of General Internal Medicine*, 17, 28-29.
12. Matched and mismatched unrelated cord blood (UCB) stem cell transplant (SCT) in adults: Preliminary results of a single insitution prospective trial - Chen, W., Visweshwar N., Ohja et al. *BLOOD*. Vol. 102. No. 11.
13. Correlation of sepsis-syndrome to the degree of immunosuppression in patients with HIV infection - Visweshwar, I., et al. *Journal of General Internal Medicine* 17 (2002): 132-133.
14. Response To Steroid Therapy Of Factor Viii Specific Inhibitor In Hepatitis-c Virus Infection - Visweshwar, N., et al. *Journal of General Internal Medicine* 18 (2003): 94-95.
15. Right Ventricular Infarction Precipitating A Bidirectional Shunt In A Patient With Incidental ASD - Visweshwar, N. I., et al. *Journal of General Internal Medicine* 18 (2003): 94.
16. Biological Determinants To Measure Adherence To Treatment In Patients With Aids - Visweshwar, N., et al. *Journal of General Internal Medicine* 17 (2002): 215.
17. Acute Myopericarditis Presenting As MI - Visweshwar, N., et al. *Journal of General Internal Medicine* 18 (2003): 95.

Career Development:

I attended the seminar titled “Scholarly paper and Protocol writing”, arranged by Dr. Jane Carver in USF on November 2015

Service:

- *University:*

Since arriving as a faculty member in Internal medicine in summer of 2013, I have established a successful Infusion Service in Morsani building and a thriving hemophilia/hematology program in USF. As Director of the hemophilia program I am responsible for administration of coagulation factor concentrates, keep a log of the factor use in our on-demand program for hemophilia. I have increased the number of hemophilia patients through continuous outreach programs. I have established hyper-coagulation clinic in USF for patients in Tampa Bay area. I am the facilitator of the infusion services at Morsani building, where Biologics, immunoglobulin and IV antibiotics are infused for various autoimmune disorders including

multiple sclerosis, collagen vascular disorders and infective disorders. Through constant dialogue with the physicians, administrators, billing and other personnel, I have streamlined running of our Infusion center. With steadily increasing number of patients, we have recruited a full- time ARNP to oversee the patients in infusion center. In the Hemophilia Treatment Center (HTC) we have increased the referral base by development of relationships with hemophilia foundations, support groups, and brought awareness of our resources and clinic to the clinicians. We have established a transition clinic for children with hemophilia to be transitioned to our adult HTC, in collaboration with All Children's Hospital Hemophilia Treatment Center. Brought community involvement through outreach programs. Clinical education in Hematology has increased with opening our clinics and inpatient services to students, residents and fellows. Increased our presence in educational programs at TGH. I continue to support our hematology/oncology fellowship program in collaboration with the Moffitt Cancer Center. Research initiated by CDC, ATHENS and Industry has increased with increasing scientific publications, grant application and clinical trials. Developed collaborative projects with the Division of Evidence-Based Medicine, Moffitt Cancer Center, and other intramural and external scientist/institutions. Our core capabilities are the outstanding faculty and unique patient populations. We have the only adult HTC in Florida with one of the largest population of patients with inherited bleeding disorders. This presents our trainees with a very unique educational experience. Improving our Infusion Center in Morsani building has been one of the main area of focus, since my arrival in USF. Our clinical operations have been reorganized to maximize our resources and minimize the expenses. We have opened our Infusion Center to all services, not only to clinicians in USF, but also the outside clinicians needing infusion services for Biologics, drug trials and for infusion of IV fluids and antibiotics for their patients. The numbers are steadily increasing. With recruitment of a nurse practitioner in the infusion center, the physicians are freed from their presence during the infusion period.

- *Professional:*

I have organized the TGH hematology clinic and inpatient service to allow for rapid growth, development of disease specific expertise. Established pathways and guidelines that guarantee the highest level of care for our patients. Increased the referral base by advertising to our peers, educational programs, participation in multidisciplinary conferences and increase communication. I participate in multidisciplinary (medical oncology, radiation oncology and surgical team with weekly tumor boards to implement a personalized approach to patient care. In TGH, we have set up the "bloodless committee" for helping Jehovah's Witness for undergoing major surgical procedures without use of blood products. I coordinate with patient, the family and the spiritual leaders with a special emphasis on building up rapport, to improve the hematological status of the patient with improvement of hemoglobin with erythropoietin preoperatively. Expectant use of anti-fibrinolytics and IV Iron has helped early recovery of the bone marrow from postoperative anemia. I am planning to set up an "Anemia Clinic" in TGH to prevent unnecessary delay and hospitalization of patients needing pre-op work up in the hospital. Tampa General Hospital, one of the largest tertiary care hospitals in the state, we currently see approximately 90% of hospitalized patient with hematological and oncological diseases, allowing our trainees to see a broad spectrum of diseases. Our strong relationship and collaboration with Moffitt Cancer Center (an NCI designated cancer center) strengthens the educational experience of our students and trainees.

- *Community:*
 - I have taken keen interest in the welfare of veterans especially veterans of Asia-pacific origin, for which Veterans affairs have given me a certificate of appreciation. Conducted regular community outreach programs, wherein I meet up with patients regularly to discuss the recent developments in the treatment of Hepatitis C and HIV (unfortunately some of these patients have been given contaminated blood products).
 - Bridge Clinic - this is a clinic which is aimed to render unrestricted service to patients who need treatment for acute and chronic medical care. The clinic is conducted by the voluntary support from the medical students, faculty and other administered the personnel. Patients are offered clinical, laboratory and radiological facilities in the University premises at Morsani building.
 - International: Once every year as a hematologist and part of a physician member group organized by Arvelo Araujo. M.D for Mission of Mercy, we go El Salvador for about a week, treating the needy patients and follow-up arranged with local physicians, involving them in the charity work.
 - The hematology clinic at Morsani Center caters for the community of the greater Tampa Bay area. The Hemophilia Treatment Center (HTC) has been reorganized and continues to increase in volume. Our center caters for a large population in Florida, covering eastward from Orlando, westward from St. Petersburg, southward from Naples, and northward from Gainesville. We are catering to the health of young adults by creating a transition clinic with All Children's Hospital. We maintain our pharmacy relationship with the Hemophilia Alliance and Hemophilia of Georgia, where we can provide outpatient factor treatment for our patients at a significant cost savings for them through the 340b Federal Program for drug pricing. In addition, the funds from that program directly support our HTC operational budget. We see great opportunities by expanding our operations at the cancer center at TGH, the hematology clinic at Morsani Center, and the HTC.

Teaching:

- *Under graduate training:*
 - I have a first year medical student allocated for mentoring her throughout the medical curriculum. We meet once every 3 months wherein she updates me about her academic progress. She has research interest in hematology (coagulation disorders and pregnancy). I am mentoring on this project. As part of our international medicine program she is planning to travel to Netherlands, where her parents come from to foster her personal and academic interests.
- *Undergraduate course taught:*
 - BCC 6110 – Internal Medicine Clerkship – since 2013
- *Graduate training:*
 - Along with the program Director of hematology/oncology program, I have established a comprehensive hematology curriculum with special emphasis on clinical care with emphasis on Pathology mainly hematopathology. This will guide the fellows in reviewing the bone marrow/peripheral smear morphology for

comprehensive care of patients. Along with my colleagues in TGH we have established monthly hematology case discussions to improve the clinical training program. I also have fellows regularly in my hematology clinic and also supervise fellows with their independent clinics in VA Hospital.

- *Graduate course:* BCC 8117 – Interdisciplinary Oncology – since 2014
- *Fellows mentored and trained in hematology:*
 - o 2013 - Kendra Sweet, M.D. Asmita Mishra, M.D. Robert Crescentini, M.D. Ben Creelan, M.D.
 - o 2014 - Jason Brayer, M.D. Elizabeth Byron, M.D. Julio Chavez, M.D. Smir Dalia, M.D. Scott Haake, M.D. Richard Hall, M.D. Wasif Riaz, M.D.
 - o 2015 - Catherine Baksh, M.D. Amber Flaherty, M.D. Nishi Kothari, M.D. Blessi Matthew, M.D. Gopi Prithviraj, M.D. Michael Tees, M.D. Matt Whitehurst, M.D.
 - o 2016 - Melanie Sheen, M.D. David Sallman, M.D. Monique Sajjad, M.D. Danny Nguyen, M.D. Patrick Griffin, M.D. Josephine Emole, M.D. Nishan Tchemedian, M.D.
 - o 2017 - Apuri Susmitha, M.D. Bustamante Liliana MD Byer Jennifer MD Chaudhury Ateefa MD Dhulipala Varun MD Grabska Joanna MD Haider Mintallah MD Kim Dae Won MD Sandoval-Sus Jose MD Shafique Michael MD
- *International teaching:*
 - o At Royal postgraduate medical school, London hematology/ hematopathology training – I am part of the external faculty in their annual training program.
 - o Visiting faculty member in Hemophilia and hemostasis training program – for graduate trainees in Christian medical College, Vellore, India.

Administration:

- Director of the hemophilia program
 - o I am responsible for administration of coagulation factor concentrates; keep a log of the factor use in on-demand program for hemophilia.
- Tampa General Administrative Roles
 - o I am in the bloodless committee for helping Jehovah's Witness for underlying major surgical procedures without use of blood products. I coordinate with patient, the family and their spiritual leaders with a special emphasis on building up hemoglobin with erythropoietin, preoperatively and expectant use of anti-fibrinolytics and IV Iron for early recovery of the bone marrow from postoperative anemia.
- USF Health Morsani Center for Advanced Health-
 - o I am the facilitator of the infusion services at Morsani building, where Biologics, immunoglobulin and IV antibiotics are infused for various autoimmune and general medical disorders including multiple sclerosis, collagen vascular disorders and infective disorders.

Editorial board member of following Journals:

1. Journal of blood- Gavin publishers
Editor - Nicholas Cook, M.D
2. International Journal of hematology and therapy - Omega publishers
Editor – Ygal Rotenstrich, M.D
3. Journal of Hematology and Myeloma
Remedy publishers

Editor – Shannon Scott, M.D

4. International Journal of biological systems -SciDoc Publishers

Editor – Soren Hassing, M.D

Trials (sponsored):

Protocol List:

1. ILIAD: IL-2 an Alternative dose: Treatment of Patients with Metastatic Renal Cell Carcinoma with Low Dose Proleukin.
2. BAYERI00365: A single Agent BAY 56-3722, uncontrolled phase II study in patients with advanced or metastatic colorectal cancer, who are considered resistant/refractory to Irinotecan.
3. Z-Fast: an Open label randomized multicenter study to evaluate the use of Zoledronic acid in the prevention of Cancer Treatment related bone loss in postmenopausal women with ER+ and/or PR+ Breast Cancer receiving Letrozole as adjuvant therapy.
4. ZENECA-9331IL/0024 -A phase II, open randomized, multicenter trial to assess the efficacy and tolerability of intravenous ZD 9331 given as monotherapy or in combination with topotecan, in patients with ovarian cancer refractory or recurrent after failing platinum and paclitaxel in combination.
5. BCIRG 005: A multicenter phase III randomized trial comparing combination with doxorubicin and cyclophosphamide (TAC) vs. doxorubicin and cyclophosphamide followed by docetaxel (AC-T) as adjuvant treatment of operable breast cancer HER2neu negative patients with positive axillary lymph nodes.
6. BCIRG 006: Multicenter phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (Ae.T H) and with docetaxel, platinum salt and trastuzumab (TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER2neu alteration.
7. Protocol C-20001.003: A multicenter randomized study of Vincristine, Doxil and Dexamethasone vs. Vincristine, doxorubicin and dexamethasone in patients with multiple myeloma.
8. Interferon gamma 1b in combination with chemotherapy (carboplatin/paclitaxel) for first line therapy of advanced ovarian or primary peritoneal carcinoma.
9. Randomized phase II trial to evaluate the effect of gemcitabine plus R115777 vs. gemcitabine plus placebo on time to deterioration in patients with advanced pancreatic cancer.
10. CTI1060: Phase II clinical trial of arsenic trioxide and dexamethasone for relapsed or refractory multiple myeloma.
11. OSI 2298g_A phase III, randomized double blind multicenter trial of OSI-774 (erlotinib) plus chemotherapy (carboplatin and paclitaxel) vs. chemotherapy alone in patients with advanced stage IIIB or IV non-small cell lung cancer who have not received prior chemotherapy.
12. POI-OI-003-050: A randomized, multicenter study of combination therapy followed by subsequent single agent gemcitabine maintenance therapy or Best Supportive Care in advanced non small cell lung cancer.
13. 4001.00.001: an open label randomized controlled phase III multicentered clinical trial of PN401 with high dose 5FU vs. gemcitabine for treatment of patients with advanced pancreatic cancer.

14. N91-00-02-040: Clinical protocol for a randomized, double blind placebo controlled comparison of the analgesics activity of valdecoxib 40 mg BID as add on therapy to opioid medication in patients with chronic cancer pain. (closed)
15. 104864-A: An open label multicentered randomized phase III study comparing oral topotecan/cisplatinum vs. etoposide/cisplatinum as treatment for chemotherapy naive patient with extensive disease small cell lung cancer.(closed)
16. L54389-33 A multicenter, phase II evaluation of ONTAK (denileukin diftitox) in patients with previously treated low or intermediate Grade B cell Non-Hodgkin's lymphoma (closed)
17. AMG20020122: A randomized, open label, multicenter study of primary prophylaxis with pegfilgrastim vs. secondary prophylaxis as an adjunct to chemotherapy in Elderly subjects (65 years old) with cancer.
18. AMG 20010144 A double blind placebo controlled multicenter randomized study evaluating the prophylactic use of pegfilgrastim on the incidence of febrile neutropenia in subjects with advanced breast cancer treated with single agent docetaxel.
19. AMG 20020778: randomized double blind phase II study evaluating safety of same day vs. next day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with breast cancer.
20. LIL/LUN04: a phase II, open label, prospective randomized controlled multicenter study of navelbine in combination with gemzar vs. paraplatin in combination with Taxol in chemotherapy naive subjects with inoperable stage IIIB or IV non-small cell lung cancer: a quality of life study.
21. CT-2103/Carboplatin versus Pacitaxel/Carboplatin for the treatment of PS 2 patients with chemotherapy naive advanced non-small Cell Lung cancer (NSCLC): A phase III study.
22. PGI-02-004-020 Final v2 A Multicenter, Retrospective Survey of the Incidence of Anemia and Outcomes of Erythropoietic Therapy in Patients Receiving Systemic Chemotherapy for Cancer (closed)
23. CT-2103 versus Docetaxol for the second line treatment of Non-Small Cell Lung Cancer (NSCLC): Phase III study.
24. PR02-27-016 An Open labeled Pilot Study to evaluate the effects of high dose Procrit in maintaining hemoglobin levels in anemic cancer patients receiving Chemotherapy on an every 3-week regimen.
25. PR02-27-015 An Open labeled Pilot Study to evaluate the effects of high dose Procrit in maintaining hemoglobin levels in anemic cancer patients receiving Chemotherapy on an every 4-week regimen.
26. LORIVIRIP03/002 A Phase III, double blind, multicenter, randomized study in Chemonaive patients with locally advanced or metastatic pancreatic cancer to compare a combination therapy of Virulizin plus Gemcitabine versus placebo plus Gemcitabine; optional second line therapy may include continuation of Viruzilin or placebo, alone or in combination with 5-Fluorouracil.
27. Helsinn Palo 004, 005, 006 -Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
28. 20020132 - A study to assess symptom burden in subjects with nonmyeloid malignancies receiving chemotherapy and Aranesp
29. PR02-27-015 An Open labeled Pilot Study to evaluate the effects of high dose Procrit in maintaining hemoglobin levels in anemic cancer patients receiving Chemotherapy on an every

- 4-week regimen.30.20000220: An open label randomized study to develop a screening tool for functional capacity in anemic subjects with nonmyeloid malignancies receiving chemotherapy and NESP (closed).
30. Solvay S1753102 A double-blind, randomized, placebo-controlled, parallel-group of oral Dronabinol alone and in combination with Ondansetron versus Ondansetron alone in subjects with delayed Chemotherapy-induced nausea and vomiting.
 31. PALO-03-06 Phase 2 Open Label Piolet safety and efficacy study of concomitant Palonosetron (Aloxi) and Aprepitant (Emend) therapy for the prevention of CINV in cancer patients receiving moderately emetogenic chemotherapy.
 32. PALO-04-08-A phase 2, open-label, multicenter study to assess the safety and efficacy of Aloxi (Palonosetron HCl) when premixed and infused with dexamethasone 8 mg in a prehydration solution for the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin, cyclophosphamide, doxorubicin or oxaliplatin.
 33. NAFTA Phase III Study of Tamoxifene versus Toremifene as adjunct therapy for women with Breast Cancer.
 34. POI-02S17 A multicenter, Open-label Study of Nipent, Cytoxan, and Rituxan in the treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-cell Non-Hodgkin's Lymphoma.
 35. POI-02818 A Multicenter, open-Label Study of Nipent, Cytoxan, and Rituxan in Patients with Previously Untreated Chronic Lymphocytic Leukemia.
 36. AMG20030204 A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects with Anemia of Cancer Patients not currently taken Chemotherapy. 38.AMG20030206 SYNCHRONICITY: A Study to Evaluate the Effectiveness of Aranesp® at 300 Meg Q3W on Clinical Outcomes in Cancer Patients With Anemia Due to Chemotherapy.
 37. Strakan Patch Study 392MD/15/C A randomized, active control, double-blinded, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system in chemotherapy-induced nausea and vomiting or highly emetogenic multi-day chemotherapy.
 38. Palo-03-13 ALOXI - A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
 39. Palo-03-14 ALOXI - A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
 40. DACO-020 A Phase 2 Study of decitabine Administered Daily for 5 days Every 4 Weeks to Adults with Advanced-Stage Myelodysplastic Syndromes.
 41. Z-Fast CZOL446E US32 An open-Label, Randomized, Multicenter
 42. Study to Evaluate the use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/orPR+ Breast Cancer receiving Letrozole as Adjuvant Therapy.
 43. Z-Next Registry Protocol CZOL446EUS99 A dual-Cohort, prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis.
 44. Abbott M05-7S2 A Phase Ⅱ Study evaluating the Safety and Efficacy of ABT 751 in Combination with Docetaxel vs. Docetaxel Alone in
 45. Subjects with Advanced or Metastatic NSCLC.

46. DOXILOVC2007 A single ann Study of Carboplatin and DOXIL plus Bevacizumab in Subjects with Platinum Sensitive Recurrent Ovarian Cancers.
47. Amgen 20050232, A Randomized Double- Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Subjects with Low or Intermediate Risk Myelodysplastic Syndrome Receiving Hypomethylating Agents.
48. Amgen 20060102 A Randomized, Double Blind, Placebo Controlled
49. Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomid.
50. C2006-01 Phase 3 Randomize Clinical Trial of the Efficacy and Safety of APF530 compared to ALOXI for Prevention of Acute and delayed CINV following Moderate or highly emetogenic Chemotherapy.
- 51.3160A4-3000- WW - A Phase 3 Randomized, Open-label Study of Bosutinib versus Imatinib in Subjects with Newly Diagnosed Chronic Philidelphia Chromosome Positive Chronic Myelogenous Leukemia
- 52.Luitpold IVIT08019 A Multi-center, Randomized, Controlled Study to Investigate the safety and Tolerability of Interavenous Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia
- 53.Luitpold IVIT08020 A Multi-center, Randomized, Controlled Study to Investigate the safety and Tolerability of Interavenous Ferric Carboxymaltose (FCM) vs Iron Dextran in Treating Iron Deficiency Anemia
- 54.Luitpold IVIT08021 A Multi-center, Randomized, Controlled Study to Investigate the safety and Tolerability of a Single Dose of Interavenous Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent
- 55.EISAI E7373-AOOI-401 A Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of Dacogen vs Vidaza for injection in subjects with Int-1 and High risk MDS
- 56.LF-0207 - FORTIS-M A Phase 3, Randomized, Double-blind, Placebo-controlled study of oral talatoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens
57. AMG 20060198 A Randomized, Double-blind, Placebo -Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Int-1 MDS
- 58.EPO-ANE- 3010 A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients with Metastatic Breast Cancer Receiving Standard Chemotherapy
- 59.AMG 20060198 A Randomized, Double-blind, Placebo -Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Int-1 MDS
- 60.EISAI E7389-GOOO-301 A Phase 3 Open-label, Randomized Two-Parallel-Arm Multicenter Study of E7389 vs Capecitabine in Patients with Locally

Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Therapy

- 61.EC-FV .04 A Randomized Trial Comparing EC145 and Pegylated Liposomal Doxorubicin in Combination vs. Pegylated Liposomal Doxorubicin alone in Subjects with Platinum resistant Ovarian Cancer
- 62.PGT307 Paclitaxel poliglumex (CT-2103)/Carboplatin vs. Paclitaxel/Carboplatin for the treatment of Chemotherapy-Naive Advanced NSCLC in women with Estradiol < 30pg/ml
- 63.MM-121-02-02-03 A randomized Double-Blind Phase 2 trial of Exemestane +/- :MJVI12th Postmenopausal Women with locally advanced or Metastatic Estrogen receptor positive and/or Progesterone Receptor positive, HER 2 negative Breast Cancer
- 64.PALO 08-09 Multicenter Phase IV, Open Label to assess the efficacy and safety of single dose Palonosetron in the prevention of CINV in Patients with NHL undergoing repeated cycles of Chemotherapy
- 65.AMG20070782 A randomized, Double blind Placebo controlled study to evaluate long term safety and efficacy of Aranesp administered at 500mcg every 3 weeks in anemic patients with Advanced stage NSCLS receiving multiple Chemotherapy
- 66.KLT-PANC-OOI A randomized dose Escalation, Safety and Exploratory Efficacy Study ofKanglaite Injection Plus Gemzar vs Gemzar alone in Advanced Pancreatic Cancer
- 67.AMAG-FER-IDA-301 Phase 3 Randomize Double blind, Placebo Controlled trial ofFerumoxytol for IDA
- 68.AMAG-FER-IDA-303 Phase 3 Open label Extension Trial of the Safety and Efficacy of Ferumoxytol for IDA
- 69.LUX-BI 1200.75 An Open -label, Randomized Phase 3 trial of BIBW2992 and Vinorelbinevs Trastuzumab and Vinorelbine in patients with Metastatic HER2 -Overexpressing Breast Cancer failing one prior Trastuzumab treatment
- 70.GWCA0962 A Randomized Double- Blind, Placebo-Controlled, Parallel group study of Sativex oromucosal spray (Sativex nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistant Chronic Pain in Patients with Advance Cancer, who Experience Inadequate analgesia during Optimized chronic Opioid Therapy
- 71.GWCA0999 A Multi-center, noncomparative, Open-label extension study to assess the long term Safety of Sativex oromucosal spray (Sativex nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistant Chronic Pain in Patients with Advance Cancer

Looking toward the Future:

1. To further improve our infusion center by making the services available, not only for physicians at USF but also other community physicians, with a target of 30-40 patients daily. Increase patient referral to our HTC through constant dialogue with the referral physicians
2. Initiate community outreach programs and set up patient support group in hemophilia in USF
3. To initiate a satellite hemophilia clinic in the east coast run by our ARNP to increase the volume of patients in our HTC
4. To start a twinning program with HTC in San Juan, which is being spearheaded by Irmel Ayala, MD to benefit hemophilia community at large
5. With the help of information technology staff in USF I am planning to get new technologies in USF (social networking, telemedicine and virtual patient care)
6. Strive hard to obtain more funding from public and private sectors for research in hemophilia - awaiting funding for our project “ comparison of patient perceived vs. ultrasound confirmed hemarthrosis in patients with hemophilia prior to factor concentrate infusion”